U.S. Markets closed

Prometic Life Sciences to Present at Canaccord 39th Annual Growth Conference

LAVAL, QC , ROCKVILLE, MD and CAMBRIDGE, United Kingdom , Aug. 5, 2019 /CNW Telbec/ - Prometic Life Sciences Inc. (PLI.TO) (OTCQX:PFSCD) (Prometic), a biopharmaceutical company focused on developing novel therapeutics to treat unmet needs in patients with liver, respiratory and kidney disease, today announced that members of the management team will provide a business overview and update at the Canaccord 39th Annual Growth Conference at 16:30 ET on Wednesday, August 7, 2019 in Boston , USA .

The presentation will be webcast live on the Webcasts page of the Investors & Media section of Prometic's website, or by following the link below in your web browser. An archived replay of the webcast will be available on Prometic's website for at least 7 days after the live event concludes.

http://wsw.com/webcast/canaccord35/pli/

About Prometic

Prometic (www.prometic.com) is an innovative biopharmaceutical corporation with a broad pipeline of small molecule therapeutics under development to treat unmet needs in patients with liver, respiratory and kidney disease, including rare diseases. Prometic's differentiated research involves the study of two G-protein-coupled-receptors, GPR40 and GPR84. These drug candidates have a dual mode-of-action as agonists ("stimulators") of GPR40 and antagonists ("inhibitors") of GPR84. Our lead drug candidate, PBI-4050, is expected to enter Phase 3 clinical studies for the treatment of Alström Syndrome. A second drug candidate, PBI-4547, is expected to enter Phase 1 clinical studies in 2019. Prometic also has leveraged its experience in bioseparation technologies to isolate and purify biopharmaceuticals from human plasma. The lead plasma-derived therapeutic product is RyplazimTM (plasminogen) which the Company expects to file a BLA with the US FDA seeking approval to treat patients with congenital plasminogen deficiency. The Corporation also operates a contract development and manufacturing operation in the United Kingdom , deriving revenue through sales of affinity chromatography media. Prometic has active business operations in Canada , the United States and the United Kingdom .

Forward Looking Statements

This presentation contains forward-looking statements about Prometic's objectives, strategies and businesses that involve risks and uncertainties. These statements are "forward-looking" because they are based on our current expectations about the markets we operate in and on various estimates and assumptions. Actual events or results may differ materially from those anticipated in these forward-looking statements if known or unknown risks affect our business, or if our estimates or assumptions turn out to be inaccurate. Such risks and assumptions include, but are not limited to, Prometic's ability to develop, manufacture, and successfully commercialize value-added pharmaceutical products, the availability of funds and resources to pursue R&D projects, the successful and timely completion of clinical studies, the ability of Prometic to take advantage of business opportunities in the pharmaceutical industry, uncertainties related to the regulatory process and general changes in economic conditions. You will find a more detailed assessment of the risks that could cause actual events or results to materially differ from our current expectations in the Annual Information Form for the year ended December 31, 2018 , under the heading "Risks and Uncertainties related to Prometic's Business". As a result, we cannot guarantee that any forward-looking statement will materialize. We assume no obligation to update any forward-looking statement even if new information becomes available, as a result of future events or for any other reason, unless required by applicable securities laws and regulations. All amounts are in Canadian dollars unless indicated otherwise.

For more information, please visit www.prometic.com.

 

SOURCE ProMetic Life Sciences Inc.


View original content: http://www.newswire.ca/en/releases/archive/August2019/05/c9266.html